Thermo Fisher Scientific Obinutuzumab Monoclonal Antibody (18H8)
인간 CD20 항원을 표적으로 하는 마우스 모노클로날 항체. Obinutuzumab를 면역원으로 제작된 18H8 클론. ELISA에 적합하며 단백질 A로 정제된 동결건조 형태. 암 연구 및 항체 반응성 분석용 연구 전용 제품.
- 카탈로그번호
- A0194540
- 판매단위
- pk
카탈로그
1개 옵션 · 카탈로그 번호를 클릭하면 복사됩니다Thermo Fisher Scientific · Thermo Fisher Scientific Obinutuzumab Monoclonal Antibody (18H8)
Applications
- ELISA (ELISA): Tested Dilution 0.005–1 µg/mL
Product Specifications
| 항목 | 내용 |
|---|---|
| Species Reactivity | Human |
| Host / Isotype | Mouse / IgG1, kappa |
| Class | Monoclonal |
| Type | Antibody |
| Clone | 18H8 |
| Immunogen | Obinutuzumab |
| Conjugate | Unconjugated |
| Form | Lyophilized |
| Purification | Protein A |
| Storage buffer | PBS, pH 7.4 |
| Contains | 0.02% sodium azide |
| Storage conditions | -20°C or -80°C if preferred |
| Shipping conditions | Ambient (domestic); Wet ice (international) |
Product Specific Information
Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
Obinutuzumab is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It was approved under the trade name Gazyva by the US FDA in 2013, and as Gazyvaro by the EMA in Europe, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients, and as a second line treatment for follicular lymphoma.
Obinutuzumab binds to CD20 on B cells and causes these cells to be destroyed by engaging the adaptive immune system, directly activating intracellular apoptosis pathways, and activating the complement system.
Target Information
Obinutuzumab is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It was approved under the trade name Gazyva by the US FDA in 2013, and as Gazyvaro by the EMA in Europe, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients, and as a second line treatment for follicular lymphoma.
Obinutuzumab binds to CD20 on B cells and causes these cells to be destroyed by engaging the adaptive immune system, directly activating intracellular apoptosis pathways, and activating the complement system.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Thermo Fisher Scientific 상품 둘러보기
전체보기
문의
0개 · 배송·재고 문의는 실시간 상담이 빠릅니다아직 등록된 문의가 없어요.